Learn more →
Back to Expert Scholars
basic / basicPediatric Oncology

Nada Jabado

纳达·贾巴多

MD, PhD, FRCP(C)

🏢McGill University / The Research Institute of the McGill University Health Centre(麦吉尔大学/麦吉尔大学健康中心研究所)🌐Canada

James McGill Professor of Pediatrics; Canada Research Chair in Pediatric Oncology麦吉尔大学詹姆斯·麦吉尔儿科教授;加拿大儿童肿瘤研究主席

61
h-index
3
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

Nada Jabado is a pioneering physician-scientist at McGill University who co-discovered histone H3 K27M and G34 mutations as founding oncogenic events in pediatric gliomas, fundamentally reshaping understanding of pediatric brain tumor biology and inspiring an entirely new field of cancer epigenetics.

Share:

🧪Research Fields 研究领域

H3K27M Histone MutationsH3K27M组蛋白突变
H3G34 GliomaH3G34胶质瘤
Pediatric Glioma Epigenetics儿童胶质瘤表观遗传学
Chromatin Remodeling染色质重塑

🎓Key Contributions 主要贡献

Discovery of H3K27M Mutation

Co-discovered the K27M mutation in histone H3.3 as the dominant oncogenic event in pediatric diffuse midline glioma, recognized as one of the most significant pediatric cancer biology findings of the decade.

H3G34 Glioma Biology

Characterized H3.3 G34R/V mutations in hemispheric pediatric high-grade glioma, revealing a distinct developmental cell-of-origin and chromatin dysregulation mechanism.

Epigenetic Therapeutic Targeting

Identified EZH2 and SETD2 pathway dependencies downstream of H3K27M, providing mechanistic rationale for epigenetic drug targeting in pediatric gliomas.

Representative Works 代表性著作

[1]

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

Nature Genetics (2012)

Co-discovery of H3.3 K27M and G34R/V mutations as hallmark alterations in pediatric high-grade gliomas.

[2]

SETD2 is a major tumor suppressor in pediatric glioma by restraining H3K36 dimethylation

Nature Genetics (2022)

Revealed SETD2 loss-of-function as a key epigenetic driver cooperating with H3G34 mutations in pediatric glioma.

[3]

Inhibition of EZH2 reverses H3K27me3 alterations and overcomes resistance in H3K27M gliomas

Science Translational Medicine (2020)

Demonstrated EZH2 inhibitor activity in H3K27M glioma models, providing preclinical basis for clinical trials.

🏆Awards & Recognition 奖项与荣誉

🏆Canada Research Chair in Pediatric Oncology (Tier 1)
🏆CIHR Foundation Grant Award
🏆ISNO Young Investigator Award
🏆Garron Family Award for Excellence in Research
🏆Prix du Québec – Marie-Victorin (Science Award)

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 纳达·贾巴多 的研究动态

Follow Nada Jabado's research updates

留下邮箱,当我们发布与 Nada Jabado(McGill University / The Research Institute of the McGill University Health Centre)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment